🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "significant breakthrough" in the effort against drug-resistant strains of the pathogen, according to health experts.

An International Public Health Issue

Gonorrhoea infections are escalating globally, with figures suggesting in excess of 82 million new cases annually. Notably increased rates are reported in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune step in the context of increasing worldwide cases, the spread of superbugs and the very limited available drugs at this time.”

Health officials are deeply concerned about the surge in drug-resistant strains. The World Health Organization has classified it as a "priority pathogen". A tracking program found that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Gain Authorization

One new antibiotic, also known as a brand name, was approved by the US FDA in mid-December for use against gonorrhoea. This STI can lead to major issues, including infertility. Scientists believe that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, was also approved in the same week. This treatment, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This milestone signifies a significant shift in the therapy of highly resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Testing Results and Global Access

According to findings published in a prominent scientific publication, zoliflodacin successfully treated the vast majority of cases of the STI. This establishes an similar efficacy with the existing first-line therapy, which uses a dual-drug approach. The research included hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the rights to register and commercialise the drug in many developing nations.

Doctors on the front lines have expressed hope. The availability of a one-pill regimen of this kind is described as a "critical tool" for public health efforts. This is deemed essential to lessen the impact of the illness for people and to halt the transmission of extremely resistant gonorrhoea around the world.